Recently added

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Triner, Daniel; Madison, Russell; Gjoerup, Ole; Tukachinsky, Hanna; ross, jeffrey; Graf, Ryon; Mateo, Joaquin (Elsevier, 2024-09)

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Chi, Ping; Somaiah, Neeta; George, Suzanne; Blay, Jean-Yves; Jones, Robin; Serrano, Cesar (Taylor & Francis, 2024)

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

Fay, Andre P; Heinrich, Daniel; Agarwal, Neeraj; Azad, Arun; Matsubara, Nobuaki; Carles, Joan (Taylor & Francis, 2024)

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Leighl, Natasha; Akamatsu, Hiroaki; Lim, Sun Min; Minchom, Anna; Marmarelis, Melina; Cheng, Ying; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2024-10-20)

SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

Marquez-Rodas, Ivan; Rodríguez Moreno, Juan F.; Arance Fernández, Ana Mª; Campos, Begoña; MUÑOZ COUSELO, EVA; Berciano Guerrero, Miguel Angel (Springer Nature, 2024-11)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing ﻿

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations ﻿

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer ﻿

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study ﻿

SEOM-GEM clinical guidelines for cutaneous melanoma (2023) ﻿

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

SEOM-GEM clinical guidelines for cutaneous melanoma (2023)